Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Glivec er større end risiciene ved behandling af ovenstående sygdomme, også dem, for hvilke der kun foreligger be - grænsede oplysninger.
The Committee for Medicinal products for Human Use (CHMP) decided that Glivec’ s benefits are greater than its risks for the treatment of the conditions listed above, including those for which limited data were available.